Boston, MA, USA – GNH India, a WHO cGSDP-certified pharmaceutical wholesaler, showcased its expertise in comparator sourcing and biosimilars at the Partnerships in Clinical Trials (PCT) Conference during Boston Biotech Week 2016, held from September 26–29 at the Hynes Convention Center. The event, a premier gathering for clinical trial professionals, provided GNH India with a platform to highlight its role in supporting global clinical trials with high-quality, cost-effective solutions from India.

The PCT Conference, part of Boston Biotech Week, brought together industry leaders, CROs, and biopharmaceutical companies to discuss innovations in clinical trial design, partnerships, and supply chain management. Dr. Piyush Gupta, Associate Director of Business Development at GNH India, presented the company’s capabilities in sourcing comparators and biosimilars, emphasizing India’s growing prominence in the global biosimilars market, which boasts nearly 100 approved biosimilars—the highest globally.

“Boston Biotech Week is a critical platform for us to demonstrate how GNH India bridges the gap between quality and affordability in clinical trial supplies,” said Dr. Gupta. “Our WHO cGSDP-certified processes ensure that we deliver compliant, high-quality comparators and biosimilars to support global research.”

GNH India’s participation highlighted its extensive network, spanning over 180 countries, and a portfolio of more than 135,000 product lines. The company’s Mumbai-based facilities, audited for compliance with GDP, GxP, and ISO standards, were showcased as a benchmark for precision and reliability. Attendees were particularly impressed by GNH India’s ability to reduce costs by up to 50% compared to traditional markets, while maintaining stringent quality standards for clinical trial supplies.

The conference also addressed key challenges in clinical trial supply chains, such as regulatory compliance and global sourcing complexities. GNH India’s smart sourcing solutions, leveraging India’s robust biosimilar ecosystem, were presented as a strategic advantage for biopharmaceutical companies seeking to optimize trial budgets without compromising quality. The event facilitated new partnerships, with GNH India engaging with global stakeholders to expand its footprint in the clinical trial supply market.

“India’s biosimilar expertise is a game-changer for clinical trials worldwide. At GNH India, we are committed to delivering value-driven solutions that empower our partners,” Dr. Gupta added.

As the global biosimilars market continues to grow, GNH India’s participation in Boston Biotech Week 2016 solidified its reputation as a trusted partner in the biopharmaceutical industry. The company’s focus on quality, affordability, and global reach positions it to meet the rising demand for biosimilars and comparators in clinical research.